Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Highlights

The phase 3 SONIA randomized clinical trial provides a critical re-evaluation of the optimal timing for cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) administration in patients with hormone receptor (HR)-positive, ERBB2-negative advanced breast cancer (ABC). The key highlights include:

• No significant difference in overall survival (OS) was observed between patients receiving CDK4/6i in the first-line setting versus those receiving it in the second-line setting (Median OS: 47.9 vs 48.1 months).
• First-line use of CDK4/6i was associated with a 42% increase in the number of grade 3 or higher adverse events compared to second-line use.
• A post hoc subgroup analysis identified a potential OS benefit for first-line CDK4/6i use in premenopausal patients (HR, 0.53), a finding that warrants further investigation.
• The results suggest that for many postmenopausal patients, starting with endocrine monotherapy and reserving CDK4/6i for progression does not compromise survival and reduces the burden of side effects.

The Evolution of Endocrine Therapy in Advanced Breast Cancer

For several decades, endocrine therapy (ET) has served as the backbone of treatment for HR-positive, ERBB2-negative advanced breast cancer. The landscape shifted dramatically with the introduction of CDK4/6 inhibitors—specifically palbociclib, ribociclib, and abemaciclib. Landmark trials such as PALOMA, MONALEESA, and MONARCH demonstrated that adding these agents to first-line aromatase inhibitors (AI) significantly prolonged progression-free survival (PFS) compared to AI monotherapy. Consequently, first-line CDK4/6i plus ET became the global standard of care.

However, despite the clear PFS benefits, questions regarding the optimal sequencing of these expensive and potentially toxic agents remained. Specifically, clinicians have debated whether the early use of CDK4/6i is necessary for all patients or if comparable long-term outcomes, such as overall survival, could be achieved by reserving these inhibitors for the second-line setting. The SONIA trial was designed to address this clinical uncertainty directly.

Study Design and Methodology

The SONIA trial (NCT03425838) is a multicenter, investigator-initiated, randomized phase 3 trial conducted across the Netherlands. It enrolled 1,050 patients with HR-positive, ERBB2-negative ABC who had not received prior systemic treatment for their advanced disease. Participants were randomized in a 1:1 ratio into two distinct treatment strategies:

Strategy A: First-Line CDK4/6i

Patients received an aromatase inhibitor (AI) combined with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) as their first-line treatment. Upon progression, they transitioned to second-line therapy with fulvestrant monotherapy.

Strategy B: Second-Line CDK4/6i

Patients received an AI as monotherapy in the first-line setting. Upon progression, they received fulvestrant combined with a CDK4/6 inhibitor as their second-line treatment.

The primary endpoint was PFS after two lines of therapy (PFS2), defined as the time from randomization to progression on second-line treatment or death. Overall survival (OS) was a key secondary endpoint. This updated analysis, published in JAMA Oncology, provides the mature OS data after a median follow-up of nearly five years (58.5 months).

Key Findings: Survival, Progression, and Toxicity

The results of the SONIA trial challenge the current paradigm of universal first-line CDK4/6i use. The data revealed that the strategic sequence of treatment did not result in a statistically significant difference in the most critical long-term outcomes.

Overall Survival (OS)

At the data cutoff on September 1, 2024, 606 deaths had occurred. The median OS for the first-line CDK4/6i group was 47.9 months (95% CI, 44.0-54.3), while the median OS for the second-line group was nearly identical at 48.1 months (95% CI, 44.7-52.0). The hazard ratio (HR) was 0.91 (95% CI, 0.77-1.07; P = .24), indicating that neither strategy was superior in terms of extending life.

Adverse Events and Toxicity

One of the most striking findings was the disparity in treatment-related toxicity. Patients in the first-line CDK4/6i group spent a significantly longer duration on the combination therapy (median 24.7 months) compared to the second-line group (median 10.1 months). This extended exposure translated into a higher incidence of adverse events. Specifically, the first-line group experienced 3,400 grade 3 or higher adverse events, compared to 2,242 in the second-line group. This represents a substantial increase in the burden of side effects, such as neutropenia, fatigue, and gastrointestinal issues, without a corresponding survival benefit.

Subsequent Therapy Patterns

The study also tracked subsequent treatments after second-line progression. Approximately 84% of patients in both groups received further anticancer therapy, with similar patterns of treatment (mostly chemotherapy or other targeted agents). This suggests that the sequencing of CDK4/6i did not negatively impact the efficacy of later-line interventions.

The Premenopausal Factor: A Post Hoc Signal

While the overall study population showed no difference in OS, a prespecified subgroup analysis focused on menopausal status yielded intriguing results. In premenopausal patients (who received ovarian function suppression), there was a suggestion of an OS benefit with first-line CDK4/6i use (HR, 0.53; 95% CI, 0.32-0.87). In contrast, postmenopausal patients showed no benefit (HR, 1.00; 95% CI, 0.84-1.19).

The P-value for interaction was 0.01, suggesting that the effect of treatment timing might indeed differ by menopausal status. However, the authors caution that this was a post hoc analysis and should be interpreted as hypothesis-generating rather than definitive. It may reflect biological differences in tumor behavior or treatment response in younger versus older populations.

Clinical Implications and Expert Commentary

The SONIA trial results have profound implications for clinical practice and health policy. For several years, the oncology community has leaned toward an ‘escalation’ approach—using the most potent combinations as early as possible. SONIA provides high-quality evidence that ‘more’ is not always ‘better’ for every patient.

Personalized Sequencing

For postmenopausal patients with low-to-moderate disease burden, starting with an aromatase inhibitor alone and reserving the CDK4/6 inhibitor for the second-line setting appears to be a safe and effective strategy. This approach spares patients from months of cumulative toxicity and frequent clinic visits for monitoring (e.g., blood counts) during the first-line period.

Financial Toxicity and Resource Allocation

CDK4/6 inhibitors are among the most expensive medications in oncology. By delaying their use to the second-line, the total duration of treatment with these agents is reduced by more than half (from 24.7 months to 10.1 months in the SONIA cohort). On a population level, this represents a massive opportunity for cost savings within healthcare systems without compromising patient survival. This is particularly relevant in resource-constrained settings or for patients facing high out-of-pocket costs.

Limitations and Considerations

Critics of the SONIA trial may point out that the choice of CDK4/6i was at the investigator’s discretion, and the majority of patients received palbociclib. Some argue that results might differ with ribociclib or abemaciclib, which have shown more robust OS benefits in their own respective first-line registration trials. Furthermore, the trial did not utilize newer biomarkers (such as circulating tumor DNA) to guide sequencing, which may be the next frontier in refining these treatment decisions.

Conclusion

The SONIA trial is a landmark study that brings much-needed clarity to the management of HR-positive, ERBB2-negative advanced breast cancer. It demonstrates that for the general population of patients, the OS achieved with first-line CDK4/6i is not superior to that achieved with second-line use. Given the significant increase in toxicity and cost associated with earlier use, the study supports a more nuanced, individualized approach to treatment sequencing. While first-line use remains a valid option—particularly in premenopausal patients or those with high-risk features—the ‘AI-first’ strategy followed by ‘Fulvestrant + CDK4/6i’ should be considered a robust and patient-centered alternative.

Funding and Trial Information

The SONIA trial was supported by the Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Insurance Board. ClinicalTrials.gov Identifier: NCT03425838.

References

1. Wortelboer N, van Ommen-Nijhof A, Konings IR, et al. Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2026;12(3):e254122. doi:10.1001/jamaoncol.2025.4122.
2. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Aromatase Inhibitors in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936.
3. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy in Endocrine-Responsive Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.
4. Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Patients With HR+, HER2- Advanced Breast Cancer (MONARCH 2). JAMA Oncol. 2020;6(1):116-124.